{
  "report_rows": [
    {
      "kpi": "Jakafi net sales",
      "prediction": "BEAT",
      "answer": "pred ~$808M vs. cons $796.5M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Opzelura net sales excluding the $246M CMS accrual reversal",
      "prediction": "MISS",
      "answer": "pred ~$210M vs. cons $214.7M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Hematology and Oncology portfolio net sales",
      "prediction": "BEAT",
      "answer": "pred ~$232M vs. cons $221M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Total net sales",
      "prediction": "BETTER",
      "answer": "guide ~$5.18B vs. cons $5.15B (FY2026 midpoint)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Opzelura net sales",
      "prediction": "BETTER",
      "answer": "guide ~$1.05B vs. cons $1.03B (FY2026 midpoint, including CMS reversal)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Jakafi net sales",
      "prediction": "BETTER",
      "answer": "guide ~$3.28B vs. cons $3.26B (FY2026 midpoint)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Hematology and Oncology portfolio net sales",
      "prediction": "BETTER",
      "answer": "guide ~$880M vs. cons $860M (FY2026 midpoint)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Non-GAAP R&D plus SG&A expense",
      "prediction": "LOWER",
      "answer": "guide ~$4.57B vs. cons $4.53B (FY2026 midpoint, including Vega upfront expense)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 2.2,
  "day1_confidence": "LOW",
  "day5_residual_pct": 3.0,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "Recurring Opzelura gross-to-net improvement and guide ~$5.18B vs. cons $5.15B support modest upward revenue revisions beyond the mechanical CMS benefit; guide ~$4.57B vs. cons $4.53B for spending and a small underlying Opzelura miss limit the magnitude.",
  "day5_confidence": "LOW"
}